Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven M. Devine, Clayton A. Smith, Jonathan A. Gutman, Daniel A. Pollyea
Abstract
Key Points Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence. Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.
Topics & Concepts
DiscontinuationMedicineIncidence (geometry)Adverse effectStem cellMaintenance therapyInternal medicineOncologyTransplantationIntensive care medicineChemotherapyBiologyPhysicsGeneticsOpticsHedgehog Signaling Pathway StudiesTumors and Oncological CasesHistiocytic Disorders and Treatments